← All trials
NCT00678418
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Oct 1, 2009
- Completion date
- Nov 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AlkermesLead sponsor
- Northern State Medical UniversityOverall official - principal investigator
- Bekhterev Psychoneurological Research InstituteOverall official - principal investigator
- Kazan State Medical UniversityOverall official - principal investigator
- Moscow Medical AcademyOverall official - principal investigator
- Leningrad Addiction Treatment & Research CenterOverall official - principal investigator
- Russian Academy of Medical SciencesOverall official - principal investigator
- Smolensk State Medical AcademyOverall official - principal investigator
- Saint-Petersburg State Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.